Human EGFR / HER1 / ErbB1 Protein (Fc Tag)

ERBB,ERBB1,HER1,mENA,NISBD2,PIG61

• 100ug (NPP1247) Please inquiry

Catalog Number	P10001-H02H
Organism Species	Human
Host	Human Cells
Synonyms	ERBB,ERBB1,HER1,mENA,NISBD2,PIG61
Molecular Weight	The recombinant human EGFR/Fc chimera is a homodimeric protein. The reduced monomer consists of 860 amino acids and has a calculated molecular mass of 95 kDa. As a result of glycosylation, the recombinant protein migrates as an approximately 130-140 kDa protein in SDS-PAGE under reducing conditions.
predicted N	Leu 25
SDS-PAGE
Purity	> 97 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the extracellular domain (Met 1-Gly 645) of human EGFR (NP_005219) was fused with the Fc region of human IgG1 at the C-terminus.
Bio-activity	Measured by its binding ability in a functional ELISA . Immobilized recombinant human EGF at 10 μg/ml (100 μl/well) can bind human EGFR with a linear range of 0.64-400 ng/ml.
Research Area	Signaling |Signal Transduction |Protein Phosphorylation |Tyrosine Kinase |Receptor Tyrosine Kinases
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.
Reference	Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25. Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48. Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.